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Objectives. Our aim was to evaluate the influence of a calcium 
channel blocking agent of the dihydropyridine group (nicardi- 
pine) on coronary vasomotion during dynamic exercise. 
Background. Coronary vasomotion plays an important role in 
the pathophysiology of myocardial ischemia. 
Methods. Twenty-nine patients with coronary artery disease 
were studied at rest and during bicycle exercise with the use of 
biplane quantitative coronary angiography. Twelve patients with- 
out pretreatment (group 1) served as control subjects. Seventeen 
patients (group 2) received nicardipine, either 0.2 mg by intra- 
coronary injection (n = 9) or 2.5 mg intravenously (n = 8) before 
exercise. 
Results. In the control group there was exercise-induced vaso- 
constriction (-29%, p < 0.001) of the stenotic segment but 
coronary vasodilation (+22%, p < 0.05) of the normal vessel 
segment. In group 2, nicardipine induced coronary vasodilation of 
both the normal (+16%, p < 0.001) and the stenotic vessel 
segment (+35%). During subsequent exercise there was some 
additional vasodilation of normal (+4%, p = NS) and stenotic 
arteries (+5%, p = NS). There was no difference between either 
intracoronary or intravenous nicardipine with regard to vasodi- 
lation. Application of sublingual nitroglycerin was associated with 
significant vasodilation of the normal vessel segment in groups 1 
(+18%, p < 0.05) and 2 (+15%, p < 0.001). The stenotic vessels 
showed asignificant increase in percent cross-sectional rea after 
nitroglycerin in groups 1 (+12%, p = NS) and 2 (+51%, p < 
0.001). Exertional angina pectoris occurred less frequently in 
group 2 (18%) than in group 1 (67% [p < 0.005 vs. group 2]); 
group 2 also had a smaller increase in mean pulmonary artery 
pressure (+14 vs. +21 mm Hg, p < 0.05). 
Conclusions. Exercise induces vasoconstriction f stenotic, but 
vasodilation of normal, coronary vessel segments. Intravenous 
and intracoronary nicardipine prevent vasoconstriction of ste- 
notic coronary arteries during exercise and exert a significant 
anti-ischemic effect. The combination of two anti-ischemic drugs, 
nitroglycerin and nicardipine, has an additive ffect on coronary 
vasomotion that is seen only in the stenotic vessel segment. Thus, 
the anti-ischemic action of nicardipine is mainly due to a primary 
elect on coronary vasomotor response rather than to secondary 
effects uch as changes in loading conditions. 
(J Am Coil Cardiol 1995;26:624-31) 
Coronary vasomotion plays an important role in the regulation 
of myocardial perfusion (1-3). Not only normal but also 
stenotic coronary arteries show vasomotion (4). Recently, 
vasoconstriction f stenotic oronary, arteries during exercise 
was reported (3), whereas normal coronary, arteries howed 
vasodilation. The ability of stenotic arteries to change diameter 
is due to the fact that -70% of all stenotic lesions have a 
normal musculoelastic wall segment within the stenosis (5-7). 
It was postulated that the observed exercise-induced stenosis 
narrowing is due to active vasoconstriction i duced by in- 
creased levels of circulating catecholamines (8-10), insufficient 
release of endothelium-derived r laxing factor (that is, endo- 
thelial dysfunction), enhanced platelet aggregation due to 
turbulent blood flow with release of thromboxane A: and 
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serotonin or to a passive collapse of the normal wall segment 
within the stenosis (that is, Venturi mechanism) (11). Previ- 
ously, it has been shown (12) that intracoronary application of 
diltiazem, a calcium channel blocker, prevents exercise- 
induced vasoconstriction f stenotic oronary arteries. Calcium 
antagonists influence cardiovascular hemodynamics byseveral 
different mechanisms: coronary and peripheral vasodilation, 
cardioprotective action and prolongation of atrioventricular 
conduction. The resulting hemodynamic effects vary according 
to the specific action of each drug (13). 
The dihydropyridines constitute a distinct category of cal- 
cium channel blockers that have marked peripheral vascular 
effects with minimal or no electrophysiologic a tions on the 
heart. Nicardipine hydrochloride is a newer agent that has 
undergone xtensive valuation in the past. Unlike other 
dihydropyridines, it can be administered both intravenously 
and orally. Additional differences between its properties and 
those of other calcium channel blockers have been reported: 
Nicardipine is associated with a large increase in coronary 
blood flow (14-16). Nicardipine has no or only minimal 
negative inotropic effect and can counteract the potential 
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deleterious effects of beta-blockers by increasing ejection 
fraction (17) and normalizing cardiac output (18). The present 
report focuses on the effect of intracoronary and intravenous 
administration f nicardipine on the response of normal and 
stenotic arteries to dynamic exercise in patients with coronary 
artery disease. The rationale for administering icardipine by 
two different routes was to differentiate between primary 
effects--that is, direct action on the smooth vasculature 
through intracoronary administration--and secondary ef- 
fects-that is, changes in loading conditions and contractility 
induced by intravenous administration. 
Methods  
Study patients. A total of 29 patients with coronary artery 
disease were included in the present analysis. Group 1, the 
control group, consisted of 12 patients with coronary artery 
disease given no pharmacologic treatment before exercise, the 
average age was 53 years. All 12 patients had a history of stable 
angina pectoris and 8 had had a previous myocardial infarc- 
tion. Group 2 consisted of 17 patients with coronary artery 
disease who received either intracoronary (group 2a) or intra- 
venous (group 2b) nicardipine before exercise. The nine 
patients in group 2a had an average age of 62 years; all had a 
history of stable angina pectoris and two had had a previous 
myocardial infarction. These patients received 0.2 mg of 
intracoronary nicardipine before xercise. The eight patients in 
group 2b had an average age of 56 years; all had a history of 
stable angina pectoris and one of the eight had had a previous 
myocardial infarction. These eight patients received 2.5 mg of 
intravenous nicardipine before exercise; aninth patient in this 
subgroup was excluded because he had spontaneous angina 
pectoris after left ventricular angiography and, thus, was not 
given intravenous nicardipine. 
Randomization was performed only for the two treatment 
groups. However, all three groups were well matched with 
regard to clinically relevant characteristics. 
Inclusion criteria. Patients were selected on a consecutive 
basis when a history of stable, effort-related angina pectoris 
and a clearly visible coronary artery stenosis optimal for 
quantitative evaluation were present. In all patients an exercise 
test was performed uring cardiac catheterization. Patients 
were randomly assigned to either intravenous or intracoronary 
infusion of nicardipine. For safety reasons, only patients with 
systolic blood pressure >100 mm Hg were included. 
Coronary risk factors. Six coronary risk factors were evalu- 
ated: 1) Hypercholesterolemia, defined as total cholesterol 
>200 mg/100ml. 2) History of arterial hypertension, defined as 
treatment with antihypertensive drugs by the referring physi- 
cian. 3) Smoking. Patients were classified as nonsmokers if they 
had never smoked or if they had stopped smoking at least 1 
year before the study. All other patients were classified as 
smokers. 4) Family history of coronary artery disease. Such a 
history was considered present if at least one of the patient's 
parents or a sibling <60 years old (19,20) had documented 
coronary artery disease. 5) Obesity. Patients were classified as 
obese if their body mass index was ->28 kg/m 2 (21) at the time 
of cardiac atheterization. 6) Diabetes mellitus. Three patients 
had a history of insulin-dependent diabetes mellitus; one 
patient had noninsulin-dependent diabetes. 
Cardiac catheterization. Patients underwent right and left 
heart catheterization for diagnostic purposes. Informed con- 
sent was obtained from all patients. Medication was stopped 
->24 h before cardiac atheterization. Premedication consisted 
of 10 nag of chlordiazepoxide administered orally 1 h before 
the procedure. Aortic pressure was measured with an 8F 
Judkins catheter and pulmonary artery pressure was deter- 
mined with a 6F pacing catheter with a side lumen for pressure 
measurements. All patients underwent biplane left ventricular 
angiography followed by diagnostic oronary arteriography. 
An interval of ->10 rain was allowed for dissipation of the effect 
of the contrast material. A nonionic ontrast material (iopam- 
idoltrometamol; lopamiro 370) was used for quantitative cor- 
onary angiography to minimize hyperemic reactions with tran- 
sient changes in coronary blood flow (5). Quantitative coronary 
angiography was performed in the right and left anterior 
oblique projections; but in some patients craniocaudal ngu- 
lation was necessary for proper visualization of the stenotic 
segment. Cine film was used as a data carrier (filming rate 
50 frames/s). 
Study protocol. The protocol of the present study has been 
approved by the local ethics committee. At the end of diag- 
nostic catheterization biplane coronary arteriography was car- 
ried out at rest and during bicycle exercise (bicycle rgometer; 
Siemens-Elema AG, model 380B). Exercise was begun at 50 to 
75 W and the work load was increased every 2 rain in 
increments of25 to 50 W until it matched -70% of the work 
load the patient achieved in the upright position before 
catheterization. 
Group 1 received no vasoactive substances before exercise. 
In group 2a, 0.2% mg intracoronary nicardipine was injected 
over 30 s before xercise and in group 2b 2.5 nag of nicardipine 
was administered intravenously over 5 rain. The dose of 0.2 mg 
represents -20% of the systemically active dosage. These 
doses of nicardipine were chosen on the basis of previously 
published ose-response curves indicating that an intracoro- 
nary dose of 0.2 mg and an intravenous dose of 2.5 mg of 
nicardipine are larger than the reported maximal vasodilating 
dose (21,22). Immediately after nicardipine a second angio- 
gram was acquired. Then bicycle exercise was begun. At the 
end of each of the two exercise levels, coronary angiography 
was repeated. Exercise was stopped when the submaximal 
work load was achieved or when symptoms developed; then, 
1.6 mg of nitroglycerin was administered sublingually and 
coronary angiography was repeated 5 rain later. 
Quantitative coronary angiography. Quantitative valua- 
tion of biplane coronary arteriograms was performed with a 
semiautomatic computer system (23). Evaluation was per- 
formed in blinded fashion in the control group and 20 of the 17 
patients in group 2; that is, the observer was unaware of the 
actual study situation. For each step, two to three end-diastolic 
frames were evaluated and averaged to reduce biologic varia- 
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Figure 1. Biplane coronary angiograms at 
rest (top panels), after injection of 0.2 mg 
of nicardipine into the left coronary artery 
(center panels) and during subsequent 
supine bicycle xercise (bottom panels). 
The lumen area of the stenosis ncreased 
from 0.8 mm 2 (top) to 1.3 mm 2 after 
intracoronary injection of nicardipine 
(center) and to 1.5 mm ~ during exercise 
(bottom). 
tions in vessel dimensions. The system is based on a 35-ram 
film projector (Tagarno A/S, Horsens, Denmark), a slow-scan 
charge couple device camera (for image digitation) developed 
at the Institute for Biomedical Engineering in Zurich, and a 
computer workstation (Apollo DN 3000, Apollo Computer 
AG, Wangen, Switzerland) for image storage and processing. 
Calibration was performed by the isocenter technique, which 
requires two orthogonal angiographic projections, the exact 
determination of the focus-image intensifier distance and a 
reference point in the center of the two image intensifiers 
(2-mm lead marks). From these data, the exact calibration 
factor for each point of the image can be determined accu- 
rately (24). Contour detection was carried out in a biplane 
projection (Fig. 1) by using a geometric-densitometric dge 
detection algorithm (25-28). Because of foreshortening, over- 
lying vessels or contrast reflux, biplane evaluation was per- 
formed only in 21 of 34 measurements (8 tenotic segments, 13 
normal segments). However, interobserver variability with this 
method (24) was found to be small with a standard error of 
estimate for biplane data of 0.14 mm 2 (4.1% of the mean vessel 
area). 
The methodology for computerized analysis of coronary 
arteriograms has been described elsewhere (24-27,29). Briefly, 
a three-dimensional model of the vessel was constructed by 
matching center lines of the individual biplane tracings, assum- 
ing the vessel cross section to be ellipsoid. The proximal, distal 
and minimal umen areas of the stenotic vessel segments were 
calculated and printed out by the computer. The area of the 
normal vessel was calculated as the average of the proximal 
and distal measurements. 
Statistical analysis. Statistical comparisons of hemody- 
namic and angiographic data at rest and during exercise as well 
as after nicardipine administration were carried out by a 
two-way analysis of variance for repeated measurements. 
When the analysis was significant, the Scheffe procedure was 
applied. Comparisons between different groups were per- 
formed by an unpaired Student test. Data are reported as 
mean value _+ 1 SD unless otherwise indicated. 
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Table 1. Patient Characteristics at Baseline* 
Group 1 Group 2 
(control) (nicardipine) 
(n = 12) (n = 17) 
Men 100% 88% 
Age (yr) 53 _+ 7 58 + 8 
NYHA functional class 1.9 +_ 0.7 2.1 + 0.5 
Body mass index (kg/m 2) 25 ± 2 26 -+ 4 
Risk factors 
Hypertension 17% 53% 
Family history of CAD 17% 41% 
Diabetes 25% 5% 
Obesity 0% 23% 
Smoking 50% 52% 
Medication 
Beta-blockers 75% 88% 
Calcium channel blockers 50% 59% 
Nitrates 50% 59% 
Triple therapy 25% 29% 
Lipid-lowering drugs 0% 18% 
Serum lipids 
Total cholesterol (nag/t00 ml) 231 +_ 38 222 _+ 38 
HDL cholesterol (rag/100 ml) 45 ± 8 (n = 3) 44 ± 10 (n = 4) 
LDL cholesterol (rag/100 ml) 146 ± 54 (n = 3) 141 ± 31 (n = 4) 
Triglycerides (rag/100 ml) 165 ± 67 174 ± 130 
*There were no significant differences between groups. Data are expressed 
as mean value - SD or percent of group. CAD = coronary artery disease; HDL 
and LDL = high and low density lipoprotein, respectively; NYHA = New York 
Heart Association. 
Resu l ts  
Patient characteristics. Gender distribution, age, New 
York Heart Association functional classification and body 
mass index were comparable inthe two groups. Risk factors for 
coronary artery disease and the use of anti-ischemic drugs were 
evenly distributed among the study patients. Total serum 
cholesterol, high and low density lipoprotein cholesterol and 
serum triglyceride values did not differ significantly between 
the two groups (Table 1). 
Clinical and exercise data. Data for upright and intracath- 
eterization supine bicycle exercise are listed in Table 2. No ST 
segment elevation was observed in the upright exercise test 
before cardiac atheterization. The mean work load was 129 W 
in group 1, which is equal to 82% of the age-, gender- and 
height-corrected predicted normal value, and 121 W (82%) in 
group 2 during upright bicycle exercise and 81 W (51%) in 
group 1 and 83 W (57%) in group 2 during supine bicycle 
exercise (all p = NS for intergroup comparisons but p < 0.005 
for upright vs. supine position). Mean heart rate and the 
rate-pressure product were similar during exercise in both 
groups for upright and supine exercise. 
Hemodynamic data. Ejection fraction was normal in 
groups 1 and 2 (61% vs. 65%). Mean aortic pressure decreased 
slightly after administration of nicardipine, whereas mean 
pulmonary pressure remained unchanged (Fig. 2). During 
subsequent exercise both mean aortic and mean pulmonary 
artery pressures increased but decreased significantly after 
Table 2. Results of Upright and Intracatheterization Supine Bicycle 
Exercise Test 
Group 1 Group 2 
(control) (nicardipine) 
(n = 12) (n = 17) 
Upright bicycle exercise 
Work load 
At maximal exercise (W) 129 _+ 36 121 _+ 40 
% of predicted work capacity (%) 82 ± 19 82 _+ 20 
Heart rate (beats/rain) 124 ± 16 121 _+ 17 
Blood pressure (mm Hg) 
Systolic 160 + 31 164 ± 28 
Diastolic 76 -+ 13 84 _+ 13 
RPP (Xl00) (ram Hg/min) 200 -+ 59 199 _~ 49 
ST $ 0.16 +-- 0.09 0.16 - 0.13 
Angina pectoris (incidence by ehi-square test) 7/12 (58%) 8/17 (47%) 
Supine bicycle exercise 
Work load 
At maximal exercise (W) 81 + 34* 83 - 271" 
% of predicted work capacity (%) 51 + 18' 57 _+ 16" 
Heart rate (beats/rain) 99 + l l t  112 +_ 26 
Blood pressure (ram Hg) 
Systolic 147 _+ 29 148 + 25 
Diastolic 79 + 13 78 - 11 
RPP (xl00) (mm Hg/min) 145 ± 31~ 167 - 51 
ST ], 0.13 +~ 0.06 0.1 +_ 0.09 
Angina pectoris (incidence by chi-square test) 8/12 (67%) 3/17 (18%)§ 
MPAP (ram Hg) 47 -+ 6 34 _+ 81[ 
*p < 0.001, tP < 0.005, Sp < 0.01, supine versus upright bicycle exercise. 
§p < 0.005, lip < 0.001 (by analysis of variance) versus group 1. All values are 
expressed as mean value -+ SD or number (%) of patients. MPAP = mean 
pulmonary artery pressure; RPP = rate-pressure product; ST ~ = ST segment 
depression (mV) during bicycle exercise (precordial eads for upright and 
peripheral leads for supine bicycle exercise). 
sublingual nitroglycerin (Fig. 2). As a sign of exercise-induced 
ischernia, mean pulmonary artery pressure increased more in 
the control group than in the two nicardipine-treated groups 
(Table 3), but the increase reached statistical significance only 
in a comparison of groups 1 and 2 (p < 0.05). 
The incidence of angina pectoris during supine bicycle 
exercise was significantly less in the nicardipine-treated group 
(3 of 17 patients) than in the control group (8 of 12 patients 
[p < 0.05 vs. group 1]). 
Quantitative coronary angiography. The normal vessel seg- 
ment showed coronary vasodilation during exercise in the two 
groups, and the vasodilation was enhanced after sublingual 
application of nitroglycerin (Fig. 3). Nicardipine administra- 
tion was associated with a mild but significant dilation of the 
normal vessel segment in group 2b (+1.69 mm 2 [+21%], 
p < 0.05) and somewhat less in group 2 (+0.582 mm 2 [+11%], 
p < 0.05). 
The stenotic segment showed coronary vasoconstriction f 
- -30% (-0.56 mm 2, p < 0.005) during dynamic exercise in 
group 1, which was reversible after administration of sublin- 
gual nitroglycerin. Nicardipine resulted in a slight but insignif- 
icant dilation of the stenotic vessel segment in group 2 
(+0.176 mm 2, +35%, p = NS). In contrast o the control 
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Figure 2. Changes inmean aortic pressure (MAP) and mean pulmo- 
nary artery pressure (MPAP) during exercise in the control group 
(classic angina pectoris without pretreatment, circles) and after intra- 
coronary (IC, squares) or intravenous (IV, triangles) nicardipine, 
respectively. Ex= peak exercise; NTG sl = sublingual nitroglycerin. 
group, the pretreated group showed no longer exercise- 
induced vasoconstriction. Further although mild vasodilation 
of the stenotic vessel segment occurred during subsequent 
exercise (+5%, p = NS) and was enhanced after sublingual 
nitroglycerin. Nicardipine together with sublingual nitroglyc- 
erin was more effective for dilation of the stenotic vessel 
segment (+51%) than in the control group with nitroglycerin 
alone (+12%, p < 0.025) (Table 4). 
Discuss ion  
Nicardipine has been shown to be effective in patients with 
both vasospastic and exercise-induced angina pectoris (29). 
Previously, our group (5) reported that pretreatment with 
intracoronary nitroglycerin prevented exercise-induced vaso- 
constriction of stenotic oronary arteries, suggesting that active 
vasoconstriction is important in the pathogenesis of acute 
myocardial ischemia in patients with classic angina pectoris. 
The exact mechanism of exercise-induced vasoconstriction is 
not clear, but several possibilities have been suggested. These 
include active vasoconstriction asa result of alpha-adrenergic 
stimulation by circulating catecholamines and activation of the 
sympathetic nervous system, insufficient production of the 
endothelium-derived asorelaxing factor due to the atheroscle- 
rotic alterations of the vessel wall (30), increased platelet 
aggregation due to turbulent blood flow behind the stenosis 
with release of thromboxane A 2 and serotonin (31-36) or a 
passive collapse of the stenotic vessel due to an exercise- 
induced increase in coronary blood flow (venturi mechanism). 
The anti-ischemic action of calcium channel blockers has been 
well documented, but the exact mechanism isnot fully under- 
stood. Thus, we studied the effect of exercise on coronary 
vasomotion after pretreatment wi h intravenous and intracoro- 
nary administration f nicardipine. Dynamic exercise repre- 
sents a physiologic stimulus for coronary artery dilation that 
better eflects the daily activities of patients than do pharma- 
cologic interventions such as administration f dipyridamole or 
papaverine. Flow-mediated vasodilation of normal vessel seg- 
ments has previously been shown in humans after administra- 
tion of acetylcholine (37), papaverine (38) and adenosine (39). 
Attenuation of this flow-mediated response in patients with 
coronary artery disease has been attributed to impaired endo- 
thelial vasodilator function (37-39). 
In a previous investigation (3) we observed that the stenotic 
coronary area decreased by 29% during exercise, whereas the 
normal coronary vessel area increased by 22%. In the present 
study, pretreatment with intravenous or intracoronary nicar- 
dipine not only prevented narrowing of the stenotic oronary 
arteries during exercise but also induced vasodilation at the 
site of the stenosis. These data suggest that exercise is associ- 
ated with active vasoconstriction at the site of the stenosis. 
Thus, pretreatment with nicardipine decreases stenosis gradi- 
ent by coronary vasodilation and seems to prevent the occur- 
rence of a passive collapse within the stenosis during exercise. 
However, the contribution of the alpha-adrenergic system and 
the role of the endothelium-derived r laxing factor in the 
pathogenesis of exercise-induced stenosis narrowing are not 
clear and need to be further evaluated. 
Effect of nieardipine on coronary vasomotion: intravenous 
versus intracoronary application. Intravenous nicardipine in- 
duced a +21% increase (p < 0.05) in cross-sectional rea of 
the normal and a +23% increase of the stenotic vessel segment 
(Fig. 3). Similar increases in cross-sectional rea were found 
after intracoronary nicardipine in normal (+11%, p < 0.05) 
Table 3. Hemodynamic Response toSupine Bicycle Exercise 
Work Load 
Pts at Maximal AMAP AMPAP 
Group (no.) Exercise (W) (ram Hg) (ram Hg) 
1 (control) 12 81 +20 -+ 12 +21 -+ 5 
2 (nicardipine) 17 83 +1.5 + 11' +14 _+ 8* 
2a (intracoronary) 9 8~ +0.5 _+ 12" +12 +_ 4 
2b (intravenous) 8 80 +2.5 +_ 12i +17 _+ 10 
*p < 0.05 versus group 1. ?p < 0.01 versus group 1. AMAP = mean (+SD) change in aortic pressure; AMPAP = 
mean (_+SD) change in pulmonary arte~ pressure. 
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and stenotic (+42%) coronary artery segments. In the control 
group without pretreatment there was exercise-induced coro- 
nary vasoconstriction (-29%, p < 0.001) of the stenotic 
segment but vasodilation (+22%, p < 0.05) of the normal 
vessel segment. After sublingual nitroglycerin there was fur- 
ther dilation of the normal and stenotic vessel segments. In the 
nicardipine-treated group there was no significant change in 
coronary lumen area during exercise. Thus, exercise-induced 
vasoconstriction f the stenotic vessel was eliminated by nicar- 
dipine administration (Table 4). Application of sublingual 
nitroglycerin was associated with additional vasodilation of the 
normal vessel segment in group 2 (+15%, p < 0.001). The 
stenotic vessels howed only minor dilation after nitroglycerin 
in group 2 (+ 11%, p = NS). After intravenous administration 
of nicardipine (group 2b) there was a tendency toward greater 
vasodilation with nitroglycerin (+25%) than that observed 
after intracoronary administration (+2%, p = NS). Maximal 
vasodilation of the stenotic vessel was 51% in group 2 (p < 
0.01) and was significantly greater (p < 0.025) than that in 
group 1 (12%) (Table 4). Apparently, the combination of 
nitroglycerin and nicardipine has an additive ffect on coronary 
vasomotion that is more pronounced in stenotic than nonste- 
notic vessels. The exact mechanism of this additive ffect is not 
clear but might be related to the different mode of action of the 
two drugs: Nicardipine reduces the calcium influx into the 
smooth muscle cell, whereas nitroglycerin increases the cyclic 
guanosine monophosphate in the vascular musculature. This 
combined action on the vascular smooth musculature of the 
diseased coronary arteries appears to be responsible for the 
additive effect on the stenotic vessel segment, which exceeds 
that achieved by nicardipine or nitroglycerin alone. The 
greater vasodilation after intravenous than after intracoronary 
nicardipine administration might be due to the larger total 
dose rather than to a secondary mechanism after systemic 
application. Although no dose-response curve was determined 
for either nicardipine or nitroglycerin in this study, previous 
studies (21,22) in experimental nimals and in humans have 
Figure 3. Response ofnormal and stenotic arteries to dynamic exercise 
in control subjects without pretreatment (CONTROL) and in patients 
with intracoronary (IC) or intravenous (IV) nicardipine. The change in
lumen area during exercise (Ex) is expressed in percent of rest lumen 
area. Normal vessels (left) dilated uring exercise to 123% of rest values, 
and dilated further after sublingual nitroglycerin (NTG sl) (140%) in 
control subjects. Intracoronary nicardipine was associated with coronary 
vasodilation f the normal vessels (111% of rest values) and increased 
further during subsequent xercise (121%) and after sublingual nitroglyc- 
erin (129%). Intravenous nicardipine induced ilation of the normal 
vessels (121% of rest values) but remained unchanged during subsequent 
exercise and increased significantly after sublingual nitroglycerin (142%). 
In stenotic vessels (right), exercise-induced stenosis narrowing was asso- 
dated with a decrease in area size to 71% of the rest value in control 
subjects. Vasodilation (112% of rest values) occurred after sublingual 
nitroglycerin, which was given at the end of the exercise. Intracoronary 
nicardipine (group 2) produced vasodilation f the stenotic segment 
(142%), which persisted during exercise (144%). Intravenous nicardipine 
induced stenosis vasodilation (123%), which was enhanced during exer- 
cise (134%) and increased further after administration of sublingual 
nitroglycerin (159%). 
shown that the doses used were greater than the maximal 
vasodilation dose by at least a factor of 2. 
Clinical implications. Both intravenous and intracoronary 
nicardipine prevent exercise-induced vasoconstriction, lessen 
the frequency of exertional angina pectoris and reduce ST 
segment depression (Table 2), suggesting that the prevention 
of exercise-induced vasoconstriction might be partially respon- 
Table 4. Stenosis Vasomotion 
Changes in Lumen Area (% of rest value) 
During Maximal After Sublingual 
Group Bicycle Exercise Nitroglycerin 
1 (control) -29% ] ,  +12% I t  
2 (nicardipine) +40% +51% j
*p < 0.005. "~p < 0.05. 
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sible for the anti-ischemic effect of this drug. The rate-pressure 
product was not decreased by nicardipine because these pa- 
tients could exercise more than the control subjects as a result 
of the anti-ischemic effect of the drug. Thus, at comparable 
work loads both a decrease in oxygen consumption and an 
increase in coronary flow appear to be responsible for the 
reduction of exertional angina. Furthermore, nicardipine and 
nitroglycerin combination appear to have an additive ffect 
on coronary vasodilation mainly in stenotic vessel segments. 
This behavior could be attributed 1o the different pharmaco- 
logic actions of the two compounds. There was no influence of 
risk factors on coronary vasomotion in our study patients, 
mainly because most patients had normal or only slightly 
elevated serum cholesterol and only a small group had a 
history of hypertension. The average serum cholesterol was 
231 rag/100 ml in the control group and 222 rag/100 ml in the 
treatment group. These values are comparable to the serum 
cholesterol level previously reported by Seiler et al. (40) (their 
group 2, 223 mgjl00 ml). Coronary vasodilation during exer- 
cise in their patients, namely 18% (40), was similar to the 22% 
recorded in our control group. Thus, the present data are in 
full agreement with the previous report. 
Study limitations. The accuracy of quantitative coronary 
arteriography as been established previously in our laboratory 
(3,24). Interobserver variability' was found to be small (24), 
with a standard error of the estimate for biplane data of 4.1% 
of the mean vessel area. The changes observed in our study arc 
clearly larger than the reported angiographic resolution. 
Therefore, the observed changes after exercise or pharmaco- 
logic intervention can be considered representative. The an- 
giographic data have been presented in percent of the rest 
value for better comparison with the baseline measurements. 
Absolute data with regard to coronary cross-sectional rea 
would have given the same result, although percent changes 
may be misleading in normal and stenotic vessel segments hat 
have clearly different rest cross-sectional areas. Coronary 
blood flow was not measured in the present study; thus, no firm 
conclusion on the significance of coronary vasoconstriction can 
be made. However, in a previous tudy (41), coronary, flow 
reserve was found 1o decrease during bicycle exercise but to 
increase after pharmacologic vasodilation with papavcrine, 
suggesting that exercise-induced coronary vasoconstriction 
plays an important role in conditions of physiologic stress. 
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